Evidence map›Paper›PMID 26225219›Full record

ArticleMedicinal chemistry2013

Anti-Neoplastic Cytotoxicity of Gemcitabine-(C

C P Coyne, Toni Jones, Ryan Bear

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicinal chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

C P CoyneDepartment of Basic Sciences, College of Veterinary Medicine at Wise Center, Mississippi State University, Mississippi State, Mississippi 39762, USA.
Toni JonesDepartment of Basic Sciences, College of Veterinary Medicine at Wise Center, Mississippi State University, Mississippi State, Mississippi 39762, USA.
Ryan BearDepartment of Basic Sciences, College of Veterinary Medicine at Wise Center, Mississippi State University, Mississippi State, Mississippi 39762, USA.
Mississippi State University · US

Funding

Summer Research Experience for Veterinary StudentsT35OD010432 · OD · MISSISSIPPI STATE UNIVERSITY · PI Barbara Lee-Faubert Kaplan, Temesgen Samuel · 2012 to 2026
$1.3M
NIH HHS T35 OD010432
6 · The paper itself

Abstract

introductionGemcitabine is a pyrimidine nucleoside analog that becomes triphosphorylated and in this form it competitively inhibits cytidine incorporation into DNA strands. Diphosphorylated gemcitabine irreversibly inhibits ribonucleotide reductase thereby preventing deoxyribonucleotide synthesis. Functioning as a potent chemotherapeutic, gemcitabine decreases neoplastic cell proliferation and induces apoptosis which accounts for its effectiveness in the clinical treatment of several leukemia and carcinoma cell types. A brief plasma half-life due to rapid deamination, chemotherapeuticresistance and sequelae restricts gemcitabine utility in clinical oncology. Selective "targeted" gemcitabine delivery represents a molecular strategy for prolonging its plasma half-life and minimizing innocent tissue/organ exposure.

methodsA previously described organic chemistry scheme was applied to synthesize a UV-photoactivated gemcitabine intermediate for production of gemcitabine-(C

resultsCovalent gemcitabine-(C

conclusionGemcitabine-(C

Indexed as

Anti-HER2/neuAnti-neoplastic cytotoxicityChemotherapeutic-resistantCovalent immunochemotherapeuticDual combination anti-cancer therapyGemcitabine-(C4-amide)-[anti-HER2/neu]GriseofulvinMammary adenocarcinomaTubulin/microtubule inhibitor

Identifiers

PMID26225219
PMCPMC4516389
OpenAlexW2324030469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.